Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
2.37
Oct 23 • 3:59 PM ET Dollar change-0.04 Percentage change(-1.66%)
Aftermarket Close
2.36
Aftermarket • 7:51 PM ET Dollar change-0.01 Percentage change(-0.42%)
Index
-
Market Cap
99.83M
Enterprise Value
112.27M
Income
-8.63M
Sales
58.41M
Book/sh
0.25
Cash/sh
0.66
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
205
IPO
Feb 22, 1999
P/E
-
Forward P/E
-
PEG
-
P/S
1.71
P/B
9.36
P/C
3.61
P/FCF
-
EV/EBITDA
-
EV/Sales
1.92
Quick Ratio
4.53
Current Ratio
5.68
Debt/Eq
3.72
LT Debt/Eq
3.67
Option/Short
Yes / Yes
EPS (ttm)
-0.20
EPS next Y
-0.25
EPS next Q
-0.09
EPS this Y
1.85%
EPS next Y
5.03%
EPS next 5Y
28.19%
EPS past 3/5Y
25.94% 4.74%
Sales past 3/5Y
5.89% 13.78%
EPS Y/Y TTM
55.35%
Sales Y/Y TTM
25.59%
EPS Q/Q
20.26%
Sales Q/Q
22.08%
Insider Own
13.56%
Insider Trans
0.00%
Inst Own
50.35%
Inst Trans
2.66%
ROA
-14.48%
ROE
-96.38%
ROIC
-17.33%
Gross Margin
38.70%
Oper. Margin
-6.06%
Profit Margin
-14.78%
SMA20
-5.81%
SMA50
-15.96%
SMA200
-34.71%
Trades
Shs Outstand
42.12M
Shs Float
36.41M
52W High
5.08 -53.35%
52W Low
2.32 2.16%
Volatility
6.67% 7.71%
ATR (14)
0.17
RSI (14)
36.65
Beta
1.48
Rel Volume
1.05
Avg Volume
139.54K
Volume
146,271
Perf Week
-7.06%
Perf Month
-16.25%
Perf Quarter
-39.07%
Perf Half Y
-36.29%
Perf YTD
-32.29%
Perf Year
-18.28%
Perf 3Y
1.28%
Perf 5Y
-82.44%
Perf 10Y
-48.48%
Prev Close
2.41
Price
2.37
Change %
-1.66%
Date Action Analyst Rating Change Price Target Change
Sep-29-26Initiated Maxim Group Buy $6
Jul-13-26Initiated H.C. Wainwright Buy $7
Mar-11-26Upgrade BTIG Research Neutral → Buy $6
Dec-16-25Initiated Roth Capital Buy $6
Nov-14-25Upgrade Citizens JMP Mkt Perform → Mkt Outperform
Nov-12-25Upgrade Citizens JMP Mkt Perform → Mkt Outperform $8
Oct-17-24Initiated BTIG Research Neutral
Jul-14-23Initiated Stephens Overweight $8
May-20-22Initiated Lake Street Buy $12
Apr-02-19Reiterated Dougherty & Company Buy $12 → $9
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Waldman LawrenceDirectorJun 30 '26Option Exercise1.8812,00022,56017,338Jul 02 05:00 PM
Roman Shawn DavidChief Operating OfficerJun 15 '26Option Exercise3.2315,00048,45015,000Jun 17 05:15 PM
CITRONOWICZ MOSHESenior Vice PresidentMar 15 '26Option Exercise1.8037,00066,600493,504Mar 17 06:27 PM
Roman Shawn DavidChief Operating OfficerJan 27 '26Option Exercise1.8012,00021,60012,000Jan 29 05:21 PM
Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used by the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Surgical Aesthetics and Original Equipment Manufacturer (OEM). The Surgical Aesthetics segment consists of the Helium Plasma Technology lines, which include Renuvion and J-Plasma. The OEM segment focuses on designing, development, and manufacturing electrosurgical equipment and medical devices by producing generators, medical devices and related accessories. The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
PresidentMr. Charles D. Goodwin II
CFOMr. Matthew C. Hill CPA
Chief Operating OfficerMr. Shawn D. Roman
Senior Vice PresidentMr. Moshe Citronowicz
Chief of ConfidenceMs. Dolores Catania